LIVE 200 YEARS!!! IU1: Unveiling the Science Behind a Novel Anti-Aging Compound
An Assessment of IU1: A Novel Compound in the Pursuit of Healthy Aging
Executive Summary
The compound IU1 has recently garnered significant attention following research from Chung-Ang University, highlighting its potential in modulating cellular aging processes. IU1 is a small molecule identified as a reversible and specific inhibitor of human Ubiquitin Specific Peptidase 14 (USP14), an enzyme intrinsically linked to the proteasome, a critical component of the cell's protein degradation machinery.1 Its initial discovery emerged from a high-throughput screening effort, demonstrating a notable selectivity for USP14 over other deubiquitinating enzymes (DUBs).3
Recent investigations, particularly those led by Professor Seogang Hyun at Chung-Ang University, have explored IU1's capacity to address age-related impairments within the cellular protein quality control systems.4 A pivotal finding from this research is that IU1's inhibition of USP14 concurrently enhances both proteasome and autophagy activities, which are fundamental cellular cleanup mechanisms.4 Preclinical studies involving
Drosophila (fruit flies) have shown that IU1 treatment can ameliorate age-related muscle weakness and extend their lifespan.4 Furthermore, similar encouraging outcomes have been observed in human cell models, suggesting a broader potential for IU1 in combating aging and associated neurodegenerative conditions such as Alzheimer's and Parkinson's diseases.5
Despite these compelling scientific advancements, it is important to clarify the current developmental stage of IU1. Presently, IU1 remains a research compound, utilized primarily in in vitro (cell culture) and in vivo (animal) preclinical studies.2 Manufacturers explicitly state that IU1 is "Not for clinical or human use," underscoring its status as a tool for scientific investigation rather than a therapeutic agent.7 The notion of "200-year lifespans" often associated with longevity research is highly speculative and lacks empirical support from the current body of work on IU1. The primary focus of this research is on improving "healthspan"—the period of life spent in good health—and mitigating the progression of age-related diseases, rather than achieving radical extensions of human lifespan.4
The journey from a promising research compound to a publicly available drug is protracted, complex, and resource-intensive. It necessitates rigorous preclinical validation, followed by multiple phases of human clinical trials to establish safety and efficacy, culminating in stringent regulatory approvals. Currently, there are no ongoing human clinical trials evaluating IU1 as an anti-aging therapeutic.9 In summary, IU1 represents a significant scientific stride in understanding and potentially manipulating protein degradation pathways for anti-aging interventions and neurodegenerative disease therapies. However, it is an early-stage compound, and its widespread public accessibility remains a distant prospect.
1. Introduction to Cellular Aging and Proteostasis
Aging is an intricate biological phenomenon characterized by a progressive decline in physiological function across all bodily systems, inevitably leading to a heightened susceptibility to various comorbidities and chronic conditions.4 This universal process is a central focus of biomedical research, with scientists actively seeking strategies to decelerate its progression and ameliorate its detrimental impacts on human health.
A fundamental aspect of aging involves the disruption of protein homeostasis, or "proteostasis," which is considered a primary underlying cause of age-related decline.4 Cells are equipped with sophisticated "protein quality control" systems designed to maintain proteostasis. These systems include the ubiquitin-proteasome system (UPS) and autophagy. The UPS involves protein complexes known as proteasomes that are responsible for breaking down damaged or misfolded proteins into smaller peptides.4 Autophagy, on the other hand, is a cellular recycling process where cells degrade and repurpose larger cellular components, including aggregated proteins, through the formation of specialized vesicles.4 Both proteasomes and autophagy work in concert to prevent the accumulation of faulty proteins, which, if left unchecked, can induce cellular stress and contribute directly to the onset and progression of age-related degenerative diseases, such as Alzheimer's and Parkinson's.4
The scientific community recognizes that preserving the integrity and efficiency of these proteostasis mechanisms holds immense promise as a key strategy for enhancing longevity and, more importantly, improving the quality of life for older adults.4 The understanding that IU1 directly influences these critical cellular processes positions it as a compelling target for further investigation in the field of aging biology. This specific targeting of a well-understood mechanism of aging, rather than a generalized effect, provides a strong scientific rationale for its therapeutic exploration.
2. IU1: A Novel Modulator of Cellular Cleanup
Discovery and Identification
IU1, identified by its CAS Number 314245-33-5, is chemically designated as 1-[1-(4-Fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(1-pyrrolidinyl)ethanone.7 Its discovery stems from a comprehensive high-throughput screen of 63,052 compounds, which initially yielded 215 potential inhibitors of USP14. Among these, IU1 distinguished itself as the strongest hit, demonstrating remarkable selectivity for human USP14, with an IC50 value of 4-5 µM, while exhibiting negligible activity against eight other deubiquitinating enzymes (DUBs).1 This specificity was a critical factor in its initial characterization, published in a seminal 2010
Nature paper by Lee et al..2 The compound's ability to penetrate cells was also confirmed early in its characterization.1
The journey of IU1 into the realm of anti-aging research gained momentum when Professor Seogang Hyun of Chung-Ang University became aware of its capacity to enhance proteasomal activity during an academic conference. This observation prompted his research group to delve into IU1's potential anti-aging effects, leading to the recent publication in the journal Autophagy.4
Mechanism of Action
USP14 is a deubiquitinating enzyme that associates with the proteasome. Its primary function is to remove ubiquitin chains from proteins targeted for degradation, effectively slowing down or inhibiting their breakdown by the proteasome.1 IU1 acts by specifically inhibiting USP14, thereby removing this inhibitory "brake" on the proteasome. This results in an enhanced degradation of ubiquitinated proteins, allowing the cellular cleanup machinery to function more efficiently.2 This is a crucial distinction: IU1 does not directly activate the proteasome but rather disarms an enzyme that impedes its activity.
A particularly significant finding from the Chung-Ang University study is that IU1's inhibition of USP14 leads to a simultaneous enhancement of both proteasome activity and autophagy activity.4 This synergistic activation of two major protein quality control systems is paramount, as it suggests that IU1 taps into a deeper, interconnected regulatory network governing cellular waste management. Such a dual-action mechanism could be particularly effective in maintaining proteostasis, which is often compromised with aging.
Furthermore, IU1 has been shown to promote the degradation of specific proteins known to aggregate in neurodegenerative diseases. These include tau, a protein implicated in Alzheimer's disease, as well as TDP-43, ATXN3, and glial fibrillary acidic protein (GFAP), all of which are associated with various proteotoxic mechanisms.1 The ability of IU1 to clear these pathological protein aggregates expands its therapeutic relevance beyond general anti-aging to address specific, well-defined disease targets, representing a significant step toward developing treatments for these debilitating conditions. The inhibition of USP14 by IU1 is characterized by its rapid establishment upon administration and quick reversal upon its removal, indicating a dynamic and controllable pharmacological effect.1
Chemical and Pharmacological Profile
IU1 is a cell-permeable compound, meaning it can readily cross cell membranes to exert its intracellular effects.1 Its purity is consistently reported at high levels, typically exceeding 98% or 99.30%.1 In terms of solubility, IU1 is soluble in organic solvents such as DMSO (up to 30-51 mg/mL) and ethanol (up to 15-51 mg/mL) but is insoluble in water.7 For
in vivo applications, specific protocols have been developed to formulate IU1 using a combination of DMSO, PEG300, Tween-80, and saline to achieve suitable solubility.2 The compound is stable in powder form when stored desiccated at -20°C for 2-3 years, while solutions maintain potency for approximately one month at -20°C or six months at -80°C.2
Table 1: Key Characteristics and Mechanism of IU1
3. Preclinical Efficacy and Therapeutic Potential
The research on IU1 has yielded compelling preclinical data, primarily from in vitro (cell culture) and in vivo (animal model) studies, which collectively underscore its potential as an anti-aging therapeutic.
Efficacy in Animal Models (Fruit Flies)
A significant portion of the anti-aging research on IU1 has utilized the fruit fly, Drosophila, as a model organism.4
Drosophila is a valuable model for studying aging due to its relatively short lifespan and the remarkable similarity of its age-related muscle deterioration to that observed in humans.4 In these studies, fruit flies treated with IU1 demonstrated promising results. The compound was shown to improve age-related muscle weakness, a common hallmark of aging, and notably, it extended the overall lifespan of the flies.4 This extension of lifespan was accompanied by enhanced locomotive activity, indicating an improvement in overall health and vitality during aging.12 The alleviation of polyubiquitinated protein aggregation in the flight muscles of aging
Drosophila further supports the mechanism of action related to improved proteostasis.12 While a direct correlation between
Drosophila lifespan extension and human longevity cannot be assumed, these findings provide crucial proof-of-concept that modulating USP14 activity through IU1 can positively influence aging phenotypes in a living organism.
It is important to acknowledge that some perspectives argue against the direct translatability of fruit fly models to complex human aging processes, particularly regarding muscle deterioration, given the vast differences in lifespan and physiological complexity.5 However, the use of
Drosophila allows for rapid screening and mechanistic understanding of fundamental biological processes, providing a strong foundation for further research in more complex mammalian systems.
Efficacy in Human Cell Studies
Beyond animal models, IU1 has also demonstrated promising effects in human cell studies. These in vitro experiments have shown that IU1's synergistic enhancement of proteasome and autophagy activity, observed in fruit flies, is also replicated in human cells.4 This suggests that the fundamental cellular mechanisms targeted by IU1 are conserved across species, increasing the confidence in its potential therapeutic relevance for humans.
Furthermore, IU1 has been shown to promote the degradation of specific pathogenic proteins associated with neurodegenerative diseases. For instance, it depletes tau, TDP-43, ATXN3, and glial fibrillary acidic protein (GFAP) in proteotoxic mechanisms.1 The accumulation of these misfolded proteins is a characteristic feature of conditions like Alzheimer's and Parkinson's diseases.4 The ability of IU1 to clear these toxic aggregates positions it as a potential therapeutic agent not just for general aging, but specifically for these debilitating age-related neurodegenerative disorders. This direct link to specific disease mechanisms strengthens the scientific basis for its development.
Broader Therapeutic Implications
The findings from both Drosophila and human cell studies collectively lay the groundwork for developing treatments that target protein quality control systems to combat age-related diseases.4 The dual activation of proteasomes and autophagy by IU1 represents a novel strategy for maintaining cellular protein homeostasis, which is critical for healthy aging. This approach could potentially address a wide range of age-related pathologies where protein aggregation and impaired cellular clearance are contributing factors. The focus on improving "healthspan" and mitigating age-related diseases is a more scientifically grounded objective than the speculative pursuit of radical lifespan extension, aligning research efforts with achievable and clinically meaningful outcomes.
4. Safety Profile and Pharmacokinetics
The development of any compound into a therapeutic agent necessitates a thorough understanding of its safety profile and pharmacokinetic properties. Pharmacokinetics (PK) describes how a drug is absorbed, distributed, metabolized, and eliminated (ADME) by the body, while toxicology investigates the harmful effects of drugs.19
Current Safety Data
Presently, IU1 is designated strictly for "research use only" and is explicitly "not for clinical or human use".7 This classification means that comprehensive human safety data, typically gathered through rigorous clinical trials, is not yet available. Material Safety Data Sheets (MSDS) for IU1 indicate that it is not classified as a hazardous substance or mixture according to GHS (Globally Harmonized System) standards based on currently available data.8 However, these sheets also contain standard precautionary statements, noting that the material may be irritating to mucous membranes and the upper respiratory tract, and could be harmful by inhalation, ingestion, or skin absorption.8 These warnings are typical for research chemicals and underscore the need for careful handling in laboratory settings.
Preclinical studies have provided some initial insights into IU1's safety in in vitro and in vivo contexts. For instance, in murine embryonic fibroblasts (MEFs), IU1 showed apparent toxicity only at very high concentrations (250 µM), with slight inhibition of cell proliferation at 120 µM, and did not noticeably induce apoptosis.3 This suggests a relatively favorable toxicity profile in these specific cell lines at concentrations relevant for its biological activity (IC50 of 4-5 µM).1
However, some studies have reported potential neurotoxicity at higher concentrations. One study investigating IU1's effects on rat cerebral cortical neurons found that concentrations of IU1 greater than 25 µM, while reducing protein accumulation, were neurotoxic. This neurotoxicity was attributed not to enhanced proteasome activity, but to a decline in ATP levels and mitochondrial Complex I inhibition, mimicking the effects of mitochondrial inhibitors.10 This highlights a critical consideration for future therapeutic development: the need to identify a therapeutic window where the beneficial effects on proteostasis outweigh any potential adverse effects, especially in sensitive tissues like neurons. This also points to the complexity of drug action, where a compound might have different effects or mechanisms at varying concentrations or in different cell types.
Pharmacokinetics
Detailed pharmacokinetic studies in mammals specifically for IU1 as an anti-aging therapeutic are not extensively documented in the provided materials. General information on IU1's solubility and cell permeability is available 1, which are fundamental properties influencing a drug's ADME. The fact that IU1 is cell-permeable is a positive indicator for its potential as an orally active drug, as it suggests it can reach intracellular targets.1 However, comprehensive data on its absorption rates, distribution patterns within various tissues (especially brain penetration given its relevance to neurodegenerative diseases), metabolism pathways, and elimination half-life in mammalian systems are crucial for drug development and are not detailed in the provided snippets. The provided information about
in vivo dissolution protocols 2 indicates that researchers are working on optimizing its delivery for animal studies, but this does not equate to a full pharmacokinetic profile.
One study did show that IU1 treatment in mice following cerebral ischemia/reperfusion attenuated neuronal injury, reduced infarct volume, and improved functional recovery, suggesting systemic bioavailability and efficacy in a disease model.23 This
in vivo efficacy in mice, while not a full PK study, does provide some evidence that IU1 can reach and act on target tissues in a mammalian system.
The absence of detailed pharmacokinetic and long-term toxicity data in mammals, particularly non-rodents, is a standard gap for compounds at this early stage of research. Such studies are typically conducted in later preclinical phases to inform human clinical trial design.24
5. Current Status of Development and Public Availability
Research Compound Status
IU1 is currently classified as a "research use only" compound.7 This means it is available to scientists for laboratory experiments and preclinical studies, but it is explicitly not intended for medical, veterinary, diagnostic, therapeutic, or human consumption.7 This designation reflects its early stage in the drug development pipeline. The compound can be purchased from various chemical suppliers for research purposes.1
Absence of Human Clinical Trials
As of the available information, there are no records of IU1 being evaluated in human clinical trials specifically for its anti-aging properties or for the treatment of age-related diseases.2 Clinical trials are a multi-phase process (Phase I, II, III, IV) designed to assess a drug's safety, dosage, efficacy, and long-term effects in human volunteers.9 The absence of such trials indicates that IU1 has not yet progressed beyond the preclinical research stage for these applications. While some snippets mention IU1's use in studies related to cancer cell proliferation 26 or ischemic stroke in mice 23, these are distinct research avenues and do not constitute human anti-aging clinical trials.
Public Availability Timeline
The timeline for a research compound like IU1 to become publicly available as a therapeutic drug is typically extensive and fraught with challenges. The process generally involves:
Extensive Preclinical Development: This includes further in vivo studies in more complex animal models (e.g., rodents, non-rodents for longer-term toxicity) to gather comprehensive safety, pharmacokinetic, and pharmacodynamic data.24 This stage aims to establish a robust scientific basis for human trials.
Investigational New Drug (IND) Application: If preclinical data are sufficiently promising and safe, a pharmaceutical company would file an IND application with regulatory bodies (like the FDA in the US) to seek permission to begin human trials.
Phase 1 Clinical Trials: Small groups of healthy volunteers or patients receive the drug to assess its safety, dosage, and side effects. This phase typically takes several months to a year.9
Phase 2 Clinical Trials: Larger groups of patients (hundreds) receive the drug to evaluate its efficacy and further assess safety. This phase can last from several months to two years.9
Phase 3 Clinical Trials: Large-scale studies involving thousands of patients are conducted to confirm efficacy, monitor side effects, compare it to standard treatments, and collect information that will allow the drug to be used safely.9 This phase can take one to four years.
New Drug Application (NDA) / Biologics License Application (BLA): If Phase 3 trials are successful, the company submits a comprehensive application to regulatory agencies for market approval. This review process can take several months to years.
Phase 4 Post-Market Surveillance: After approval, ongoing studies monitor the drug's long-term effects and safety in the general population.9
Given that IU1 is currently in early preclinical stages for anti-aging applications, and considering the typical drug development timeline, it is highly improbable that it will be publicly available in the near future. The development of a novel drug can take 10-15 years or more from discovery to market, with significant attrition rates at each stage. There is no indication of any commercialization efforts or patents specifically for IU1 as an anti-aging therapeutic from Chung-Ang University or related entities in the provided information, although universities often have technology transfer centers for such purposes.28 The patents found for "anti-aging" are not directly related to IU1.29
6. Challenges and Future Directions
While the research on IU1 presents an exciting frontier in longevity science, several challenges must be addressed for its potential to be fully realized.
Translational Challenges
A primary challenge lies in the translation of promising results from fruit fly and human cell models to complex human physiology. While Drosophila offers a valuable system for initial mechanistic studies, the leap from a short-lived invertebrate to a long-lived human is substantial.5 The complexity of human aging and disease, involving multiple interconnected systems, requires extensive validation in higher mammalian models before human trials can be considered. The observed neurotoxicity of IU1 at higher concentrations in rat neuronal cultures 10 highlights the importance of careful dose-response studies and the identification of a safe and effective therapeutic window in mammals. This finding underscores that even a compound with a beneficial mechanism can have off-target or toxic effects at certain concentrations, necessitating thorough pharmacological characterization.
Need for Further Preclinical Studies
Before any human trials can commence, comprehensive preclinical studies are essential. These include:
Long-term Toxicity Studies: Evaluating the effects of chronic IU1 administration in various mammalian species to identify any cumulative toxicity or adverse long-term effects.24
Detailed Pharmacokinetic and Pharmacodynamic (PK/PD) Profiling: Understanding how IU1 is absorbed, distributed, metabolized, and excreted in mammals, and how its concentration correlates with its biological effects over time.16 This includes assessing its bioavailability and distribution to target tissues, particularly the brain, which is crucial for neurodegenerative applications.
Efficacy in Mammalian Models of Aging and Disease: Demonstrating consistent and robust anti-aging effects and disease mitigation in relevant mammalian models (e.g., aged mice or models of Alzheimer's/Parkinson's disease) to build a strong case for human translation.
Potential for Broader Therapeutic Applications
The research on IU1's ability to enhance proteasome and autophagy activity, coupled with its role in degrading pathological proteins like tau, suggests its potential extends beyond general anti-aging to specific neurodegenerative disorders.1 This focus on combating age-related diseases such as Alzheimer's and Parkinson's represents a significant and clinically relevant direction for future development. The underlying principle of targeting protein degradation pathways is a promising area for addressing a wide range of conditions characterized by protein aggregation.
Drug Development Landscape
The field of longevity research and anti-aging drug development is rapidly evolving, with numerous companies exploring diverse approaches, from cellular rejuvenation to senolytics.31 While IU1's mechanism is distinct, it operates within this competitive and high-risk landscape. Successful development will require substantial investment, robust scientific validation, and strategic partnerships to navigate the complex regulatory environment.
7. Conclusion
The discovery and ongoing research into IU1 by Chung-Ang University scientists represent a valid and significant advancement in the understanding of cellular aging and proteostasis. The compound's unique mechanism of inhibiting USP14 to synergistically enhance both proteasome and autophagy activity holds considerable promise for mitigating age-related decline and addressing neurodegenerative diseases. Preclinical data from fruit flies and human cells are encouraging, demonstrating improvements in age-related muscle weakness, extended lifespan in Drosophila, and the clearance of pathological protein aggregates implicated in conditions like Alzheimer's and Parkinson's.
However, it is imperative to maintain a realistic perspective regarding IU1's public availability. Currently, IU1 is a research-grade compound, explicitly not approved for human use, and is many years away from potential clinical application. The path forward necessitates extensive and rigorous preclinical studies to thoroughly characterize its long-term safety, pharmacokinetics, and efficacy in higher mammalian models. While the concept of radical human lifespan extension, such as "200-year lifespans," remains purely speculative, IU1's potential lies in its capacity to improve "healthspan" and offer novel therapeutic strategies for debilitating age-related diseases. The emergence of IU1 underscores the vibrant and evolving nature of longevity science, highlighting the potential of targeting fundamental cellular processes to foster healthier aging.
Works cited
IU1 | DUB | Autophagy - TargetMol, accessed July 5, 2025, https://www.targetmol.com/compound/IU1
IU1 | Deubiquitinase Inhibitor - MedchemExpress.com, accessed July 5, 2025, https://www.medchemexpress.com/IU1.html
Enhancement of Proteasome Activity by a Small-Molecule Inhibitor ..., accessed July 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2939003/
Chung-Ang University researchers identify a potential anti-aging drug - EurekAlert!, accessed July 5, 2025, https://www.eurekalert.org/news-releases/1059194
A Breakthrough in Anti-Aging: Korean Scientists Discover Lifespan-Extending Drug, accessed July 5, 2025, https://scitechdaily.com/a-breakthrough-in-anti-aging-korean-scientists-discover-lifespan-extending-drug/
Anti-Aging Drug May Prevent Age-Related Declines in Proteostasis - Technology Networks, accessed July 5, 2025, https://www.technologynetworks.com/drug-discovery/news/anti-aging-drug-may-prevent-age-related-declines-in-proteostasis-391364
IU1 | Abbexa Ltd, accessed July 5, 2025, https://www.abbexa.com/iu1
MATERIAL SAFETY DATA SHEET IU1 - UBPBio, accessed July 5, 2025, https://www.ubpbio.com/temp/MSDS_F4100.pdf
Clinical Trials | IU School of Medicine, accessed July 5, 2025, https://medicine.iu.edu/clinical-trials
Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: relevance to Alzheimer's disease - PubMed Central, accessed July 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5549686/
Role of IU1 in protein clearance may make it possible Parkinson's therapy, accessed July 5, 2025, https://parkinsonsnewstoday.com/news/role-iu1-protein-clearance-make-parkinsons-therapy/
Pharmacological inhibition of USP14 delays proteostasis-associated ..., accessed July 5, 2025, https://www.researchgate.net/publication/382967295_Pharmacological_inhibition_of_USP14_delays_proteostasis-associated_aging_in_a_proteasome-dependent_but_foxo-independent_manner
IU1 = 98 HPLC 314245-33-5 - Sigma-Aldrich, accessed July 5, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/i1911
IU1 - BPS Bioscience, accessed July 5, 2025, https://bpsbioscience.com/iu1-27227
IU1 | 99.86%(HPLC) | In Stock | DUB inhibitor - Selleck Chemicals, accessed July 5, 2025, https://www.selleckchem.com/products/iu1.html
IU1 | Usp14 inhibitor | Buy from Supplier AdooQ®, accessed July 5, 2025, https://www.adooq.com/iu1.html
Scientists can reverse brain aging in fruit flies by preventing buildup of a common protein, accessed July 5, 2025, https://newsroom.ucla.edu/releases/scientists-can-reverse-brain-aging-fruit-flies-by-preventing-buildup-of-common-protein
FlyBase Reference Report: Lim et al., 2024, Autophagy 20(12): 2752 ..., accessed July 5, 2025, http://flybase.org/reports/FBrf0261046
The Role of Pharmacokinetics in Pharmaceutical Toxicology - Open Access Journals, accessed July 5, 2025, https://www.openaccessjournals.com/articles/the-role-of-pharmacokinetics-in-pharmaceutical-toxicology-16261.html
Pharmacology and Toxicology - Indiana University School of Medicine, accessed July 5, 2025, https://medicine.iu.edu/pharmacology-toxicology
Safety Data Sheet - Cayman Chemical, accessed July 5, 2025, https://cdn.caymanchem.com/cdn/msds/10617m.pdf
Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: Relevance to Alzheimer's disease - PubMed, accessed July 5, 2025, https://pubmed.ncbi.nlm.nih.gov/28372990/
USP14 Inhibitor Attenuates Cerebral Ischemia/Reperfusion-Induced Neuronal Injury in Mice, accessed July 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5527549/
Redbook 2000: IV.C.5.b. One-Year Toxicity Studies with Non-Rodents | FDA, accessed July 5, 2025, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc5b-one-year-toxicity-studies-non-rodents
Clinical Trials | What to Expect | Resources - IU Health, accessed July 5, 2025, https://iuhealth.org/find-medical-services/clinical-trials
IU1 suppresses proliferation of cervical cancer cells through MDM2 degradation - PMC, accessed July 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7545697/
In Vivo Studies - Safety Pharmacology - Charles River Laboratories, accessed July 5, 2025, https://www.criver.com/products-services/safety-assessment/safety-pharmacology/vivo-studies
Centers | Academics - CHUNG-ANG UNIVERSITY, accessed July 5, 2025, https://neweng.cau.ac.kr/cms/FR_CON/index.do?MENU_ID=930
US20010012524A1 - Anti-aging agent - Google Patents, accessed July 5, 2025, https://patents.google.com/patent/US20010012524A1/en
WO2017069401A1 - Composition for alleviating skin wrinkles - Google Patents, accessed July 5, 2025, https://patents.google.com/patent/WO2017069401A1/en
Top 20 Most Innovative Longevity Biotechs in the World (2025) | Tips and Tricks - Scispot, accessed July 5, 2025, https://www.scispot.com/blog/top-20-of-most-innovative-anti-aging-companies-in-the-world
Comments
Post a Comment